The BLUEPRINT consortium consists of 41 partners representing 43 academic groups and 9 companies. The Principal Investigators leading the different teams are listed below. Information about the partner organisations and the local researchers involved can be found via the links of the Principal Investigators.

	principal investigator Tel.: +44 122 349 68 62 Personal website
David Adams (PhD) is a group leader at the Wellcome Trust Sanger Institute. His research interests are the identification of cancer genes using experimental organisms, particularly mouse. He is head of the mouse genomes project.

	principal investigator Tel.: +39 081 566 75 69 Personal website
Lucia Altucci (MD, PhD) is Associate Professor at the Department of Biochemistry, Biophysics and General Pathology. Her line of research is pre-clinically oriented and is based both on anticancer epigenetic drug development and on the characterization of the mechanisms of tumorigenesis and leukemogenesis. For BLUEPRINT, Lucia is leader of WP14.

	principal investigator
Ido Amit is leader of a research team at the Weizmann Institute of Science, Israel. His team studies the genomic code enabling immune cells to differentiate to specific subtypes and devise a specific response to invading pathogens.

	principal investigator Tel.: +41 223 795 707 Personal website
Stylianos Antonarakis is Professor and Chairman of Genetic Medicine. His accomplishments include the molecular bases of monogenic and complex genetic disorders. Current projects are functional genome analysis, genotype/phenotype variation, T21 pathogenesis and polygenic phenotypes.

	principal investigator Tel.: +44 207 679 09 64 Personal website
Stephan Beck (PhD, FMedSci) is Professor of Medical Genomics at the UCL Cancer Institute. He played a leading role in the sequencing of the human, mouse and zebrafish genomes and his lab has pioneered array- and sequencing-based DNA methylation reference maps and was among the first to conduct epigenome-wide disease association studies. For BLUEPRINT, he is leader of RA2.

	principal investigator Tel.: +44 131 650 56 68 University of Edinburgh – Wellcome Trust Centre for Cell Biology Personal website
Adrian Bird is Buchanan Professor of Genetics at Edinburgh University. He has worked on DNA methylation for 35 years. His laboratory has performed genome-wide ChIP-seq and MAP-seq analysis of mouse and human tissues in collaboration with the Wellcome Trust Sanger Institute.

principal investigator Tel.: +43-1/40160-70 070 Personal website

Christoph Bock is Principal Investigator at the CeMM Research Center for Molecular Medicine. He is also still associated with the Max Planck Institute for Bioinformatics. His research interests are mapping epigenetic regulation in blood and immune cells, developing methods for analyzing DNA methylation data and utilizing biomarkers for personalized cancer therapy. For BLUEPRINT he is leader of WP9.

	principal investigator Tel.: +49 731 500 445 04 Tel.2: +49 731 500 447 12 Personal website
Bernhard Boehm (MD) is Head of the Division of Endocrinology and Diabetes. He is an internationally renowned expert in clinical and experimental diabetes immunology. He studies the role of genetic factors in disease manifestation, in animal models as well as in humans on the basis of population-based approaches.

	principal investigator Tel.: +34 932 275 450 Personal website
Elías Campo (MD, PhD) is Clinical Director of the Center for Biomedical Diagnosis at HCPB and Scientific Director of the Chronic Lymphocytic Leukaemia Project within the International Cancer Genome Consortium (ICGC), one of the Editors of the current WHO Classification of the hematological neoplasms. His research is focused on malignant lymphomas.

	principal investigator Tel.: + 41 22 37 95 483 Universite de Geneve – Department of Genetic Medicine and Development Personal website
Emmanouil Dermitzakis is Professor of Genetics in the Department of Genetic Medicine and Development. His current research focuses on the genetic basis of regulatory variation and gene expression variation, non-coding DNA evolution, and the population genetics of human pathogens such as Plasmodium falciparum.

	principal investigator
Gerard Drewes is leader of Work Package 15 and Research Area 4.

	principal investigator Tel.: +44 207 679 65 00 University College London – Department of Cancer Biology Personal website
Tariq Enver (PhD) is Professor of Stem Cell Biology UCL. He is internationally recognised for his work on normal and leukaemic haematopoiesis.

	principal investigator Tel.: +34 932 607 140 Tel.2: +34 932 607 253 Institut D’investigacio Biomedica de Bellvitge – Department of Cancer Epigenetics and Biology program Personal website
Manel Esteller (MD, PhD) is a world renowned leader in the field of epigenetics and epigenomics. He has developed multiple approaches to detect changes in the epigenome of healthy individuals and different diseases, both in humans and animal models.

	principal investigator Tel.: +34 933 160 01 38 Centre for Genomic Regulation – Genes and Diseases Program Personal website
Xavier Estivill is coordinator of the Genes and Disease program and Senior Group Leader of Genetic Causes of Disease laboratory. His group is studying the contribution of non-coding RNAs and structural variations (including copy number variants, CNV) in the susceptibility to complex disorders.

	principal investigator Tel.: +44 012 233 338 34 Personal website
Anne Ferguson-Smith (PhD) studied mammalian functional genomics throughout her scientific career and is an internationally renowned expert in developmental epigenetics and parental-origin effects. For BLUEPRINT, she is leader of RA5 and WP11.

	principal investigator Tel.: +44 20 7882 6005 Personal website
Jude Fitzgibbon (PhD) is a Reader in Molecular Hematology and group leader in the Centre for Hemato-Oncology at Barts and the London School of Medicine. He is a recognized expert in the study of (epi)genetics and biomarkers in follicular lymphoma. His group pursues a patient-orientated research strategy to improve the prognosis of hematological malignancy.